Literature DB >> 21786259

Medical management of osteonecrosis of the hip: a review.

Asim Rajpura1, Andrew C Wright, Timothy N Board.   

Abstract

Osteonecrosis or avascular necrosis (AVN) of the hip is a progressive disease mainly affecting adults in their third, fourth or fifth decade of life. Studies into the natural history of the disease suggest that femoral head collapse occurs within 2-3 yrs with associated degenerative changes and at that stage arthroplasty is the most reliable treatment option. Therefore prevention of femoral head collapse is highly desirable in this young patient group. In early stage disease, before femoral head collapse (Ficat and Arlet stage 1-3) core decompression of the femoral head is currently the most widely used procedure to try to relieve intraosseous pressure in the femoral head and restore blood supply.Greater understanding of the pathogenesis of osteonecrosis has led to research into non-surgical management of early stages of the disease, including pharmacological and biophysical treatments.There may be a reduction in symptoms and evidence of prevention of disease progression following some non-surgical treatments. Further studies are needed, including trials comparing medical management with surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21786259     DOI: 10.5301/HIP.2011.8538

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  17 in total

Review 1.  Orthopedic surgery and its complication in systemic lupus erythematosus.

Authors:  Anselm Mak
Journal:  World J Orthop       Date:  2014-01-18

Review 2.  Clinical characteristics of avascular necrosis in patients with Behçet disease: a case series and literature review.

Authors:  Nuh Atas; Berivan Bitik; Ozkan Varan; Hakan Babaoglu; Abdurrahman Tufan; Seminur Haznedaroglu; Berna Goker; Mehmet Akif Ozturk
Journal:  Rheumatol Int       Date:  2018-12-17       Impact factor: 2.631

3.  What is the pain source? A case report of a patient with low back pain and bilateral hip osteonecrosis.

Authors:  Amy L Minkalis; Robert D Vining
Journal:  J Can Chiropr Assoc       Date:  2015-09

4.  Biomechanical bearing-based typing method for osteonecrosis of the femoral head: ABC typing.

Authors:  Zhennan Zhang; Tong Yu; Limin Xie; Yubin Li; Xun Ke; Yang Liu; Songmin Huang; Hao Deng; Yang Bai
Journal:  Exp Ther Med       Date:  2018-07-20       Impact factor: 2.447

5.  Midterm results of treating femoral head osteonecrosis with autogenous corticocancellous bone grafting.

Authors:  Manouchehr Vahid Farahmandi; Mohammadreza Abbasian; Farshad Safdari; Mohammad Emami Moghaddam Tehrani
Journal:  Trauma Mon       Date:  2014-10-08

6.  Fast sequences MR imaging at the investigation of painful skeletal sites in patients with hip osteonecrosis.

Authors:  Aristidis H Zibis; Sokratis E Varitimidis; Zoe H Dailiana; Apostolos H Karantanas; Dimitrios L Arvanitis; Konstantinos N Malizos
Journal:  Springerplus       Date:  2015-01-06

7.  Management of femoral head osteonecrosis: Current concepts.

Authors:  Sujit Kumar Tripathy; Tarun Goyal; Ramesh Kumar Sen
Journal:  Indian J Orthop       Date:  2015 Jan-Feb       Impact factor: 1.251

Review 8.  The use of anticoagulants for prevention and treatment of osteonecrosis of the femoral head: A systematic review.

Authors:  Peipei Guo; Fuqiang Gao; Yanhua Wang; Zhenkun Zhang; Wei Sun; Baoguo Jiang; Bailiang Wang; Zirong Li
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

9.  The therapeutic effect of negative pressure in treating femoral head necrosis in rabbits.

Authors:  Yin-gang Zhang; Xuezhi Wang; Zhi Yang; Hong Zhang; Miao Liu; Yushen Qiu; Xiong Guo
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  Extracorporeal Shockwave Therapy Modulates the Expressions of Proinflammatory Cytokines IL33 and IL17A, and Their Receptors ST2 and IL17RA, within the Articular Cartilage in Early Avascular Necrosis of the Femoral Head in a Rat Model.

Authors:  Jai-Hong Cheng; Shun-Wun Jhan; Chieh-Cheng Hsu; Hung-Wen Chiu; Shan-Ling Hsu
Journal:  Mediators Inflamm       Date:  2021-07-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.